A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors

Trial Profile

A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Irinotecan (Primary) ; Veliparib (Primary)
  • Indications Breast cancer; Cervical cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 19 May 2017 Status changed from suspended to recruiting.
    • 21 Sep 2016 Status changed from recruiting to suspended due to drug supply issues
    • 19 Jul 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top